Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

“Patients taking compounded tirzepatide injection are going to need to be transitioned to the FDA-approved drug Mounjaro or Zepbound,” Brunner said. “In many instances, it’s going to take some time.

The reconsideration follows an Oct. 11 lawsuit that prompted U.S. District Judge Mark Pittman to temporarily halt legal proceedings to give the FDA time to reassess its ruling.

On Oct. 2, the FDA announced that the nearly two-year-long shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, had ended. This was after the agency said it had confirmed the ...

Lilly has assured regulators that product availability and manufacturing capacity is enough to meet both current and projected demand in the U.S., the FDA said. The drugs, sold as Mounjaro and ...